The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)

NATerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Cardiomyopathy
Interventions
DRUG

Ranolazine

The intervention will be ranolazine therapy after the initial CPET. The initial CPET will identify patients with underlying ischemia and serve as a baseline study. Patients whose CPET results meet the criteria for ischemia will be started on Ranexa 500mg BID and advanced within one week +/-4 days to 1000mg BID. A second CPET will be performed after 4 weeks +/- 4 days of maximum therapy. CPET results before and after therapy will undergo a statistical comparison. The initial off treatment CPET measurement will serve as the control to assess changes found during therapy.

Trial Locations (1)

70506

Cardiovascular Institute of the South, Lafayette

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Cardiovascular Institute of the South Clinical Research Corporation

OTHER

NCT01705509 - The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC) | Biotech Hunter | Biotech Hunter